| Position | Action |
|---|---|
| Current price ($146.80) | Trim 25% position in tranches; avoid $150-151 rejection zone |
| Trim proceeds | Hold 15-20% in cash at ~4.3%+ yield |
| Remaining core position | Hard stop at $143.50 (below 200 SMA and July 30 low) |
P&G is a premium defensive compounder with a transformative strategic catalyst (Thorne acquisition) trading at a discount to its quality, offering asymmetric risk/reward with 6.76% total shareholder yield while waiting for margin recovery.
| Indicator | Value | Signal |
|---|---|---|
| Close (verified) | $146.80 | neutral |
| 50 SMA | $146.63 | neutral |
| 200 SMA | $145.90 | bullish |
| 10 EMA | $146.57 | neutral |
| MACD | -0.22 | bearish |
| MACD Signal | -0.07 | bearish |
| MACD Histogram | -0.15 | bearish |
| RSI | 49.85 | neutral |
| VWMA | $146.66 | neutral |
Support: 143.5 · 140 | Resistance: 148.5 · 151.6
PG trades at $146.80, hovering just above the 200 SMA ($145.90) with 50 SMA ($146.63) and 10 EMA ($146.57) forming a tight convergence band — a squeeze setup suggesting an imminent directional move. Bearish momentum (MACD -0.22 < signal -0.07) is waning per the improving histogram, while RSI neutral at 49.85 and VWMA ($146.66) near spot confirm no volume conviction. The 200 SMA is the critical support; losing it flips the bias bearish toward $140. Trade recommendation: HOLD.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight: 25% trim at $146.80 with hard stop at $143.50; re-entry on $151.62 reclaim with volume/MACD confirmation or Q1 FY27 margin recovery above 50.5%
October Q1 FY27 earnings is the primary validation event: volume growth + margin defense rotates Underweight toward Hold; margin compression persistence + buyback deceleration deepens toward Sell. Thorne acquisition close (timing TBD) is a secondary catalyst—watch for synergy guidance and integration milestones. The 07-31 COST lesson supports holding 15-20% of trim proceeds in cash rather than rotating into passive defensives at similar multiple risk.
When: Q1 FY27 gross margin recovery above 50.5% with raised guidance
Then: Re-evaluate toward Hold/Buy
Q4 softness is seasonal and cyclical, not structural, with forward EPS guidance of $7.41 implying +12% growth from TTM $6.62, while margin recovery is imminent as input costs ease
↩ rebuts: “Bear's quarter obsession treating cyclical margin compression as structural deterioration”
PG is a structurally weakening consumer staples franchise using balance sheet firepower (Thorne acquisition) to mask fundamental stagnation, not a compounder deserving premium multiples.
· concedes: PG is a Dividend King with $19B in annual operating cash flow and fortress balance sheet; Thorne acquisition could theoretically reposition PG into premium health/wellness category; Input cost inflation is cooling (palm oil, pulp, packaging, freight) — relief takes 6-9 months to flow through; 200 SMA at $145.90 is real technical support; Institutions have shown buying interest at key levels
→ vs conservative: The 'Dividend King' narrative is a distraction — when management is cutting buybacks by 73% and growing dividends at below-average rates, insiders are signaling caution, not confidence. Owning a compounder at full 22x multiples with a broken chart isn't defensive, it's stubborn.
→ vs neutral: The 'coiled spring with $0.73 converging MAs' thesis ignores that springs don't release upward when MACD is negative, buybacks are down 73%, EPS is down 14.9%, and margins are compressing. 'Hold and wait for a break' means getting whipsawed while fundamentals deteriorate — better to sell into the $150-$151 strength the lower-highs pattern is still providing.
Market Cap
$341.84B
P/E (TTM)
22.18
Forward P/E
19.81
PEG Ratio
5.57
P/B
6.43
EPS (TTM)
$6.62
Forward EPS
$7.41
Dividend Yield
3.0%
52-Week High
$167.25
52-Week Low
$137.62
50-Day MA
$147.38
200-Day MA
$148.03
Revenue (TTM)
$87.03B
Gross Profit (TTM)
$44.11B
EBITDA (TTM)
$23.66B
Net Income (TTM)
$16.05B
Net Margin
18.4%
Operating Margin
19.5%
Gross Margin (TTM)
~50.7%
ROE
30.3%
ROA
10.2%
Free Cash Flow (TTM)
$12.84B
Operating Cash Flow (TTM)
~$19.4B
Total Assets
$128.38B
Stockholders' Equity
$54.51B
Total Debt
$37.03B
Net Debt
$24.72B
Cash & Equivalents
$12.31B
Current Ratio
0.677
Goodwill/Intangibles
$62.9B
Beta
0.377
Q4 FY26 Revenue YOY
+7.4%
Q4 FY26 EPS YOY
-14.9%
Total Shareholder Yield
~6.76%
Strengths
Concerns
Procter & Gamble is a best-in-class consumer staples franchise trading at full valuation (P/E 22.18, PEG 5.57) with industry-leading 30.3% ROE and $19.4B annual operating cash flow. The Q4 FY2026 results show a mixed picture: solid 7.4% YOY revenue growth but real margin compression (gross margin 49.5% vs 51%+, EPS -14.9% YOY) from commodity, freight, and FX headwinds. The 3.0% dividend is fully covered by FCF, and total shareholder yield of ~6.8% (including buybacks) is competitive. Valuation is full but not extreme, with the primary near-term risk being whether margin recovery occurs in FY2027. Best suited for income-oriented, defensive, long-term positioning rather than momentum trades.